Document:

Exhibit

          4.1

      

       

      

      WARRANT AGREEMENT

       

      

      THIS WARRANT AGREEMENT (this “Agreement”), dated as of July 11, 2019, is by and between SC Health Corporation, a Cayman
        Islands exempted company (the “Company”), American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as warrant agent (in such capacity, the “Warrant Agent”), and SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”).

       

      

      WHEREAS, the Company has entered into that certain Private Placement Warrants Purchase Agreement, with the Sponsor (the “Private

          Placement Warrants Purchase Agreement”), pursuant to which the Sponsor agreed to purchase an aggregate of 5,000,000 warrants (or 5,450,000 warrants in the aggregate if the Over-allotment Option (as defined below) in connection with the
        Offering (as defined below) is exercised in full) simultaneously with the closing of the Offering (and the closing of the Over-allotment Option, if applicable) bearing the legend set forth in Exhibit A hereto (the “Private Placement Warrants”) at a purchase price of $1.00 per Private Placement Warrant; and

       

      

      WHEREAS, the Company has entered into that certain Forward Purchase Agreement (the “Forward Purchase Agreement”) with SC
        Health Group Limited, a Cayman Islands exempted company (the “Purchaser”), pursuant to which the Company agreed to issue Forward Purchase Warrants (the “Forward Purchase Warrants”) to the Purchaser in a private placement transaction to occur immediately prior to the closing of the Company’s initial Business Combination (as defined below); and

       

      

      WHEREAS, in order to finance the Company’s transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor may, but are
        not obligated to, loan to the Company funds as the Company may require, of which up to $2,000,000 of such loans may be convertible into up to an additional 2,000,000 warrants, which will be identical to the Private Placement Warrants, at a price of
        $1.00 per warrant; and

       

      

      WHEREAS, the Company is engaged in an initial public offering (the “Offering”) of units of the Company’s equity
        securities, each such unit comprised of one Ordinary Share (as defined below) and one-half of one redeemable Public Warrant (as defined below) (the “Units”) and, in connection therewith,
        has determined to issue and deliver up to 7,500,000 warrants (or up to 8,625,000 warrants to the extent the underwriter’s over-allotment option is exercised) to public investors in the Offering (the “Public Warrants” and, together with the Private Placement Warrants and the Forward Purchase Warrants, the “Warrants”).  Each whole Warrant entitles the holder thereof to
        purchase one Class A Ordinary Share of the Company, par value $0.0001 per share (“Ordinary Share”), for $11.50 per share, subject to adjustment as described herein; and

       

      

      WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement
        on Form S-1, File No. 232240 (the “Registration Statement”), and prospectus (the “Prospectus”) for the registration, under the
        Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public Warrants and the Ordinary Shares included in the Units; and

      
        
          

      

      WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer,
        exchange, redemption and exercise of the Warrants; and

       

      

      WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation
        of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

       

      

      WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the
        Warrant Agent (if a physical certificate is issued), as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.

       

      

      NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

       

        

      1. Appointment of Warrant Agent.  The Company hereby appoints the Warrant Agent to act as agent for the Company for the
          Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

       

        

      2. Warrants.

       

        

      2.1 Form of Warrant.  Each Warrant shall be issued in registered form only, and, if a physical certificate is issued,
          shall be in substantially the form of Exhibit B hereto, the provisions of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairman of the Board, President, Chief Executive Officer, Chief
          Financial Officer, Secretary or other principal officer of the Company.  In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before
          such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.  All of the Public Warrants shall initially be represented by one or more book-entry certificates (each a “Book-Entry Warrant Certificate”).

       

        

      2.2 Effect of Countersignature.  If a physical certificate is issued, unless and until countersigned by the Warrant
          Agent pursuant to this Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof.

       

        

      2.3 Registration.

       

        

      2.3.1 Warrant Register.  The Warrant Agent shall maintain books (the “Warrant Register”) for the registration of original issuance and the registration of transfer of the Warrants.  Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of
          the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company.  All of the Public Warrants shall initially be represented by one or more Book-Entry Warrant
          Certificates deposited with The Depository Trust Company (the “Depositary”) and registered in the name of Cede & Co., a nominee of the Depositary.  Ownership of beneficial interests
          in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for each Book-Entry Warrant Certificate, or (ii) institutions that have accounts with
          the Depositary (each such institution, with respect to a Warrant in its account, a “Participant”).

      
        
          

      

      If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other
        arrangements for book-entry settlement.  In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the
        Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants (“Definitive Warrant Certificates”).  Such Definitive Warrant Certificates shall be in the form annexed hereto as Exhibit B with appropriate insertions, modifications and omissions, as provided
        above.

       

        

      2.3.2 Registered Holder.  Prior to due presentment for registration of transfer of any Warrant, the Company and the
          Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute owner of such Warrant and of each
          Warrant represented thereby (notwithstanding any notation of ownership or other writing on a Definitive Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other
          purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

       

        

      2.4 Detachability of Warrants.  The Ordinary Shares and Public Warrants comprising the Units shall begin separate
          trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks in New York City are generally open for normal business (a “Business Day”), then on the immediately succeeding Business Day following such date, or earlier (the “Detachment Date”) with the
          consent of Credit Suisse Securities (USA) LLC but in no event shall the Ordinary Shares and the Public Warrants comprising the Units be separately traded until (A) the Company has filed a current report on Form 8-K with the Commission containing
          an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds received by the Company from the exercise by the underwriter of its right to purchase additional Units in the Offering
          (the “Over-allotment Option”) if the Over-allotment Option is exercised prior to the filing of the Form 8-K, and (ii) a second or amended current report on Form 8-K to provide updated
          financial information to reflect the exercise of the underwriter’s Over-allotment Option, if the Over-allotment Option is exercised following the initial filing of such current report on Form 8-K, and (B) the Company issues a press release and
          files with the Commission a current report on Form 8-K announcing when such separate trading shall begin.

       

        

      2.5 Fractional Warrants.  The Company shall not issue fractional Warrants other than as part of Units, each of which is
          comprised of one Class A Ordinary Share and one-half of one Public Warrant.  If, upon the detachment of Public Warrants from Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down
          to the nearest whole number the number of Warrants to be issued to such holder.

      
        
          

      

      2.6 Private Placement Warrants; Forward Purchase Warrants.

       

        

      2.6.1 The Private Placement Warrants shall be identical to the Public Warrants, except that so long as they are held by the
          Sponsor or any of its Permitted Transferees (as defined below), the Private Placement Warrants: (i) may be exercised for cash or on a cashless basis, pursuant to subsection 3.3.1(c) hereof, (ii) may not be transferred, assigned or sold
          until the date that is thirty (30) days after the completion by the Company of an initial Business Combination (as defined below), and (iii) shall not be redeemable by the Company; provided, however, that in the case of (ii), the
          Private Placement Warrants and any Ordinary Shares held by the Sponsor or any of its Permitted Transferees and issued upon exercise of the Private Placement Warrants may be transferred by the holders thereof:

       

        

      (a) to the Company’s officers or directors, any affiliate or family member of any of the Company’s officers or directors or
          any affiliate of the Sponsor or to any member(s) of the Sponsor or any of their affiliates or shareholders,

       

        

      (b) in the case of an individual, as a gift to such person’s immediate family or to a trust, the beneficiary of which is a
          member of such person’s immediate family, an affiliate of such person or to a charitable organization,

       

        

      (c) in the case of an individual, by virtue of the laws of descent and distribution upon death of such person,

       

        

      (d) in the case of an individual, pursuant to a qualified domestic relations order,

       

        

      (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in
          connection with the consummation of a Business Combination at prices no greater than the price at which the Warrants were originally purchased,

       

        

      (f) by virtue of the laws of the Cayman Islands upon dissolution of our Sponsor,

       

        

      (g) in the event of the Company’s liquidation prior to consummation of the Company’s initial Business Combination, or

       

        

      (h) in the event that, subsequent to the consummation of an initial Business Combination, the Company completes a liquidation,
          merger, share exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their Ordinary Shares for cash, securities or other property; provided, however, that, in the case
          of clauses (a) through (f), these transferees (the “Permitted Transferees”) enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this
          Agreement.

       

        

      2.6.2 The Forward Purchase Warrants shall have the same terms and be in the same form as the Public Warrants.

      
        
          

      

      3. Terms and Exercise of Warrants.

       

        

      3.1 Warrant Price.  Each Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant
          and of this Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. 

          The term “Warrant Price” as used in this Agreement shall mean the price per Ordinary Share at which Ordinary Shares may be purchased at the time a Warrant is exercised.  The Company in
          its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days, provided, that the Company shall provide at least twenty (20) days prior written
          notice of such reduction to Registered Holders of the Warrants and, provided further that any such reduction shall be identical among all of the Warrants.

       

        

      3.2 Duration of Warrants.  A Warrant may be exercised only during the period (the “Exercise Period”) commencing on the later of: (i) the date that is thirty (30) days after the first date on which the Company completes a merger, share exchange, asset acquisition, share purchase, reorganization or
          similar business combination, involving the Company and one or more businesses (a “Business Combination”), or (ii) the date that is twelve (12) months from the date of the closing of the
          Offering, and terminating on the earlier to occur of: (w) 5:00 p.m. New York City time on the date that is five (5) years after the date on which the Company completes its initial Business Combination, (x) the liquidation of the Company in
          accordance with the Company’s amended and restated memorandum and articles of association, as amended from time to time (the “Charter”), if the Company fails to consummate a Business
          Combination, or (y) other than with respect to the Private Placement Warrants, 5:00 p.m. New York City time on the Redemption Date (as defined below) as provided in Section 6.3 hereof (the “Expiration Date”) or (z) the Alternative Redemption Date (as defined below); provided, however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in
          subsection 3.3.2 below, with respect to an effective registration statement.  Except with respect to the right to receive the Redemption Price (as defined below) or the Alternative Redemption Price (other than with respect to a Private
          Placement Warrant) in the event of a redemption (as set forth in Section 6 hereof), each outstanding Warrant (other than a Private Placement Warrant in the event of a redemption for cash) not exercised on or before the Expiration Date
          shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date.  The Company in its sole discretion may extend the duration of the Warrants by
          delaying the Expiration Date; provided, that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be
          identical in duration among all the Warrants.

       

        

      3.3 Exercise of Warrants.

       

        

      3.3.1 Payment.  Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the
          Registered Holder thereof by delivering to the Warrant Agent at its Compliance Department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants to be
          exercised (the “Book-Entry Warrants”) on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent
          to the Depositary from time to time, (ii) an election to purchase (“Election to Purchase”) any Ordinary Shares pursuant to the exercise of a Warrant, properly completed and executed by
          the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depositary’s procedures, and (iii) payment in full of the
          Warrant Price for each full Ordinary Share as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the Ordinary Shares and the issuance of such
          Ordinary Shares, as follows:

       

        

      (a) by certified check payable to the order of the Warrant Agent or by wire transfer;

      
        
          

      

      (b) in the event of a redemption pursuant to Section 6 hereof in which the Company’s board of directors (the “Board”) has elected to require all holders of the Warrants to exercise such Warrants on a “cashless basis,” by surrendering the Warrants for that number of Ordinary Shares equal to the
          quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined in this subsection 3.3.1(b)) over the Warrant Price by (y) the Fair
          Market Value. Solely for purposes of this subsection 3.3.1(b), Section 6.2 and Section 6.4, the “Fair Market Value” shall mean the average reported closing price of the Ordinary Shares for the ten (10) trading days ending
          on the third trading day prior to the date on which the notice of redemption is sent to the holders of the Warrants, pursuant to Section 6 hereof;

       

        

      (c) with respect to any Private Placement Warrant, so long as such Private Placement Warrant is held by the Sponsor, the
          Purchaser or their Permitted Transferee, by surrendering the Warrants for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the excess
          of the “Fair Market Value” (as defined in this subsection 3.3.1(c)) over the Warrant Price by (y) the Fair Market Value.  Solely for purposes of this subsection 3.3.1(c), the “Fair Market Value” shall mean the average reported
          closing price of the Ordinary Shares for the ten (10) trading days ending on the third trading day prior to the date on which notice of exercise of the Warrant is sent to the Warrant Agent; or

       

        

      (d) as provided in Section 8.4 hereof.

       

        

      3.3.2 Issuance of Ordinary Shares on Exercise.  As soon as practicable after the exercise of any Warrant and the
          clearance of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificates, as applicable, for the number
          of full Ordinary Shares to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as
          applicable, for the number of Ordinary Shares as to which such Warrant shall not have been exercised.  If fewer than all the Warrants evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the records maintained
          by the Depositary, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding the foregoing, the Company shall not be obligated to
          deliver any Ordinary Shares pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the Ordinary Shares underlying the Public
          Warrants is then effective and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations under Section 8.4.  No Warrant shall be exercisable and the Company shall not be obligated to issue Ordinary
          Shares upon exercise of a Warrant unless the Ordinary Shares issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the
          Registered Holder of the Warrants.  In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant and such
          Warrant may have no value and expire worthless, in which case the purchaser of a Unit containing such Public Warrant shall have paid the full purchase price for the Unit solely for the Ordinary Share underlying such Unit.  Subject to Section
            4.6 of this Agreement, a Registered Holder of Warrants may exercise its Warrants only for a whole number of Ordinary Shares.  In no event will the Company be required to net cash settle the Warrant exercise.  The Company may require holders
          of Public Warrants to settle the Warrant on a “cashless basis” pursuant to subsection 3.3.1(b) and Section 8.4.  If, by reason of any exercise of Warrants on a “cashless basis,” the holder of any Warrant would be entitled, upon
          the exercise of such Warrant, to receive a fractional interest in an Ordinary Share, the Company shall round down to the nearest whole number, the number of Ordinary Shares to be issued to such holder.

      
        
          

      

      3.3.3 Valid Issuance.  All Ordinary Shares issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly
          issued, fully paid and non-assessable.

       

        

      3.3.4 Date of Issuance.  Each person whose name is set out in the register of members of the Company shall have become
          the holder of record of such Ordinary Shares on the date on which the Warrant or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate in
          the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have become the
          holder of such Ordinary Shares at the close of business on the next succeeding date on which the share transfer books or book-entry system are open.

       

        

      3.3.5 Maximum Percentage.  A holder of a Warrant may notify the Company in writing in the event it elects to be subject
          to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such election.  If the election is made by a holder, the Warrant
          Agent shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the
          Warrant Agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) (the “Maximum Percentage”) of the Ordinary Shares outstanding immediately
          after giving effect to such exercise.  For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by such person and its affiliates shall include the number of Ordinary Shares issuable upon exercise of the
          Warrant with respect to which the determination of such sentence is being made, but shall exclude Ordinary Shares that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and
          its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or
          convertible preferred shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein.  Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall
          be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  For purposes of the Warrant, in determining the number of
          outstanding Ordinary Shares, the holder may rely on the number of outstanding Ordinary Shares as reflected in (1) the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public
          filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or American Stock Transfer & Trust Company, LLC (in such capacity, the “Transfer Agent”) setting forth the number of Ordinary Shares outstanding.  For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm
          orally and in writing to such holder the number of Ordinary Shares then outstanding.  In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of equity securities of the Company
          by the holder and its affiliates since the date as of which such number of outstanding Ordinary Shares was reported.  By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage
          applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

      
        
          

      

      4. Adjustments.

       

        

      4.1 Share Capitalizations.

       

        

      4.1.1 Split-Ups.  If after the date hereof, and subject to the provisions of Section 4.6 below, the number of
          outstanding Ordinary Shares is increased by a share capitalization payable in Ordinary Shares, or by a split-up of Ordinary Shares or other similar event, then, on the effective date of such share capitalization, split-up or similar event, the
          number of Ordinary Shares issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding Ordinary Shares.  A rights offering to holders of the Ordinary Shares entitling holders to purchase Ordinary
          Shares at a price less than the “Fair Market Value” (as defined below) shall be deemed a share capitalization of a number of Ordinary Shares equal to the product of (i) the number of Ordinary Shares actually sold in such rights offering (or
          issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Ordinary Shares) and (ii) one (1) minus the quotient of (x) the price per Ordinary Share paid in such rights offering divided by
          (y) the Fair Market Value.  For purposes of this subsection 4.1.1, (a) if the rights offering is for securities convertible into or exercisable for Ordinary Shares, in determining the price payable for Ordinary Shares, there shall be
          taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (b) “Fair Market Value” means the volume weighted average price of the Ordinary Shares as reported during the
          ten (10) trading day period ending on the trading day prior to the first date on which the Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.  No Ordinary Shares
          shall be issued at less than their par value.

       

        

      4.1.2 Extraordinary Dividends.  If the Company, at any time while the Warrants are outstanding and unexpired, shall pay
          a dividend or make a distribution in cash, securities or other assets to the holders of the Ordinary Shares on account of such Ordinary Shares (or other shares of the Company’s share capital into which the Warrants are convertible), other than
          (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of the Ordinary Shares in connection with a proposed initial Business Combination, (d) to
          satisfy the redemption rights of the holders of the Ordinary Shares in connection with a shareholder vote to amend the Company’s Charter to modify the substance or timing of the Company’s obligation to redeem 100% of its Ordinary Shares included
          in the Units sold in the Offering if the Company does not complete the Business Combination within the time period set forth in the Company’s Charter, or (e) in connection with the Company’s redemption of public Ordinary Shares upon its failure
          to consummate a Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary Dividend”),

          then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other
          assets paid on each Ordinary Share in respect of such Extraordinary Dividend.  For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash
          distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the Ordinary Shares during the 365-day period ending on the date of declaration of such dividend or
          distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the
          number of Ordinary Shares issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units in the Offering).

      
        
          

      

      4.2 Aggregation of Shares.  If after the date hereof, and subject to the provisions of Section 4.6 hereof, the
          number of outstanding Ordinary Shares is decreased by a consolidation, combination, reverse share split or reclassification of Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share
          split, reclassification or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding Ordinary Shares.

       

        

      4.3 Adjustments in Exercise Price.

       

        

      4.3.1 Adjustments in Exercise Price.  Whenever the number of Ordinary Shares purchasable upon the exercise of the
          Warrants is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the
          numerator of which shall be the number of Ordinary Shares purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of Ordinary Shares so purchasable immediately
          thereafter.

       

        

      4.3.2 If (i) the Company issues additional Ordinary Shares or equity-linked securities for capital raising purposes in
          connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per Ordinary Share (with such issue price or effective issue price to be determined in good faith by the Board and, (1)
          in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (2) to the extent that such issuance is made to
          SIN Capital Group Pte. Ltd. or its affiliates, without taking into account the transfer of founder shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the
          Company) by the Sponsor in connection with such issuance) (the “Newly Issued Price”), (ii) the aggregate gross proceeds from such issuance represent more than 60% of the total equity
          proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the consummation of the Company’s initial Business Combination (net of redemptions), and (iii) the volume weighted average
          trading price of the Company’s Ordinary Shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per
          share redemption trigger price described in Section 6.1 below will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

      
        
          

      

      4.4 Replacement of Securities upon Reorganization, etc.  In case of any reclassification or reorganization of the
          outstanding Ordinary Shares (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value of such Ordinary Shares), or in the case of any merger or consolidation of the
          Company with or into another entity or conversion of the Company into another entity (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of
          the outstanding Ordinary Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is
          dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Ordinary Shares of the Company immediately theretofore
          purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of Ordinary Shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or
          consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the “Alternative Issuance” ); provided, however, that in connection with the closing of any such consolidation, merger, sale or conveyance, the successor or purchasing entity shall execute an
          amendment hereto with the Warrant Agent providing for delivery of such Alternative Issuance, and provided, further, that (i) if the holders of the Ordinary Shares were entitled to exercise a right of election as to the kind or
          amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be
          deemed to be the weighted average of the kind and amount received per Ordinary Share by the holders of the Ordinary Shares in such consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer
          shall have been made to and accepted by the holders of the Ordinary Shares (other than a tender, exchange or redemption offer made by the Company in connection with redemption rights held by shareholders of the Company as provided for in the
          Charter or as a result of the redemption of Ordinary Shares by the Company if a proposed initial Business Combination is presented to the shareholders of the Company for approval) under circumstances in which, upon completion of such tender or
          exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such
          maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange
          Act (or any successor rule)) more than 50% of the outstanding Ordinary Shares, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other property to which such holder would
          actually have been entitled as a shareholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Ordinary Shares held by such holder had been purchased
          pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4; provided, further,
          that if less than 70% of the consideration receivable by the holders of the Ordinary Shares in the applicable event is payable in the form of capital stock or shares in the successor entity that is listed for trading on a national securities
          exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the
          public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the Warrant Price shall be reduced by an amount (in dollars) equal to the difference (but in no
          event less than zero) of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below).  The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial
          Markets (“Bloomberg”).  For purposes of calculating such amount, (1) Section 6 of this Agreement shall be taken into account, (2) the price of each Ordinary Share shall be the
          volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day volatility
          obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a
          period equal to the remaining term of the Warrant.  “Per Share Consideration” means (i) if the consideration paid to holders of the Ordinary Shares consists exclusively of cash, the
          amount of such cash per Ordinary Share, and (ii) in all other cases, the volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the
          applicable event.  If any reclassification or reorganization also results in a change in Ordinary Shares covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3
          and this Section 4.4.  The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers.  In no event will the Warrant Price be reduced
          to less than the par value per Ordinary Share issuable upon exercise of such Warrant.

      
        
          

      

      4.5 Notices of Changes in Warrant.  Upon every adjustment of the Warrant Price or the number of Ordinary Shares issuable
          upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the increase or decrease, if any, in the number of Ordinary Shares
          purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.  Upon the occurrence of any event specified in Sections 4.1, 4.2,
          4.3 or 4.4, the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of the record date or the effective date of the
          event.  Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

       

        

      4.6 No Fractional Shares.  Notwithstanding any provision contained in this Agreement to the contrary, the Company shall
          not issue fractional shares upon the exercise of Warrants.  If, by reason of any adjustment made pursuant to this Section 4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest
          in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to such holder.

       

        

      4.7 Form of Warrant.  The form of Warrant need not be changed because of any adjustment pursuant to this Section 4,
          and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants initially issued pursuant to this Agreement; provided, however, that the Company may at any time
          in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an
          outstanding Warrant or otherwise, may be in the form as so changed.

       

        

      4.8 Other Events.  In case any event shall occur affecting the Company as to which none of the provisions of the
          preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this
          Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any
          adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment.  The Company shall adjust the
          terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

       

        

      4.9 No Adjustment.  For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely as a
          result of an adjustment to the conversion ratio of the Company’s Class B ordinary shares (the “Class B Shares”)
          into Ordinary Shares or the conversion of Class B Shares into Ordinary Shares, in each case, pursuant to the Company’s Charter, as amended from time to time.

       

        

      5. Transfer and Exchange of Warrants.

       

        

      5.1 Registration of Transfer.  The Warrant Agent shall register the transfer, from time to time, of any outstanding
          Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of a certificated Warrant, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer.  Upon any such
          transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent.  In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the
          Warrant Agent to the Company from time to time upon request.

      
        
          

      

      5.2 Procedure for Surrender of Warrants.  Warrants may be surrendered to the Warrant Agent, together with a written
          request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants;
          provided, however, that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry Warrant Certificate and Definitive Warrant Certificate may be transferred only
          in whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however, that in the event that a Warrant surrendered for transfer
          bears a restrictive legend (as in the case of the Private Placement Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received an opinion of counsel for the Company
          stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

       

        

      5.3 Fractional Warrants.  The Warrant Agent shall not be required to effect any registration of transfer or exchange
          which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.

       

        

      5.4 Service Charges.  No service charge shall be made for any exchange or registration of transfer of Warrants.

       

        

      5.5 Warrant Execution and Countersignature.  The Warrant Agent is hereby authorized to countersign and to deliver, in
          accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly
          executed on behalf of the Company for such purpose.

       

        

      5.6 Transfer of Warrants.  Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only
          together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit.  Furthermore, each transfer of a Unit on the register relating to such Units shall
          operate also to transfer the Warrants included in such Unit.  Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer of Warrants on and after the Detachment Date.

       

        

      6. Redemption.

       

        

      6.1 Redemption of Warrants for Cash.  Subject to Section 6.5 hereof, not less than all of the outstanding
          Warrants may be redeemed, at the option of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section
            6.3 below, at the price of $0.01 per Warrant (the “Redemption Price”), provided that the last
          sales price of the Ordinary Shares reported has been at least $18.00 per Ordinary Share (subject to adjustment in compliance with Section 4 hereof), on each of twenty (20) trading days within the thirty (30) trading-day period ending on
          the third Business Day prior to the date on which notice of the redemption is given and provided that there is an effective registration statement covering the Ordinary Shares issuable upon exercise of the Warrants, and a current prospectus
          relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.3 below) or the Company has elected to require the exercise of the Warrants on a “cashless basis” pursuant to subsection 3.3.1.

      
        
          

      

      6.2 Redemption of Warrants for Ordinary Shares.  Subject to Section 6.5 hereof, not less than all of the
          outstanding Warrants may be redeemed, at the option of the Company, commencing ninety (90) days after they are first exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice to the Registered Holders of the
          Warrants, as described in Section 6.3 below, at a price equal to a number of Ordinary Shares determined by reference to the table below, based on the redemption date (calculated for purposes of the table as the period to expiration of the
          Warrants) and the “Fair Market Value” (as such term is defined in subsection 3.3.1(b)) (the
          “Alternative Redemption Price”), provided that the last sales price of the Ordinary Shares reported
          has been at least $10.00 per share (subject to adjustment in compliance with Section 4 hereof), on the trading day prior to the date on which notice of the redemption is given and provided that there is an effective registration statement
          covering the Ordinary Shares issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.3 below) or the Company has elected to require the exercise
          of the Warrants on a “cashless basis” pursuant to subsection 3.3.1, provided that the Private Placement Warrants shall be concurrently exchanged at the same price (equal to the number of Ordinary Shares) as the Public Warrants.

       

        

      	 	 	
              Fair Market Value of Ordinary Shares

            	 
	
              Redemption Date

              (period to expiration of the Warrants)

            	 	
              $

            	
              10.00

            	 	 	
              $

            	
              11.00

            	 	 	
              $

            	
              12.00

            	 	 	
              $

            	
              13.00

            	 	 	
              $

            	
              14.00

            	 	 	
              $

            	
              15.00

            	 	 	
              $

            	
              16.00

            	 	 	
              $

            	
              17.00

            	 	 	
              $

            	
              18.00

            	 
	
              57 months

            	 	 	
              0.257

            	 	 	 	
              0.277

            	 	 	 	
              0.294

            	 	 	 	
              0.310

            	 	 	 	
              0.324

            	 	 	 	
              0.337

            	 	 	 	
              0.348

            	 	 	 	
              0.358

            	 	 	 	
              0.365

            	 
	
              54 months

            	 	 	
              0.252

            	 	 	 	
              0.272

            	 	 	 	
              0.291

            	 	 	 	
              0.307

            	 	 	 	
              0.322

            	 	 	 	
              0.335

            	 	 	 	
              0.347

            	 	 	 	
              0.357

            	 	 	 	
              0.365

            	 
	
              51 months

            	 	 	
              0.246

            	 	 	 	
              0.268

            	 	 	 	
              0.287

            	 	 	 	
              0.304

            	 	 	 	
              0.320

            	 	 	 	
              0.333

            	 	 	 	
              0.346

            	 	 	 	
              0.357

            	 	 	 	
              0.365

            	 
	
              48 months

            	 	 	
              0.241

            	 	 	 	
              0.263

            	 	 	 	
              0.283

            	 	 	 	
              0.301

            	 	 	 	
              0.317

            	 	 	 	
              0.332

            	 	 	 	
              0.344

            	 	 	 	
              0.356

            	 	 	 	
              0.365

            	 
	
              45 months

            	 	 	
              0.235

            	 	 	 	
              0.258

            	 	 	 	
              0.279

            	 	 	 	
              0.298

            	 	 	 	
              0.315

            	 	 	 	
              0.330

            	 	 	 	
              0.343

            	 	 	 	
              0.356

            	 	 	 	
              0.365

            	 
	
              42 months

            	 	 	
              0.228

            	 	 	 	
              0.252

            	 	 	 	
              0.274

            	 	 	 	
              0.294

            	 	 	 	
              0.312

            	 	 	 	
              0.328

            	 	 	 	
              0.342

            	 	 	 	
              0.355

            	 	 	 	
              0.364

            	 
	
              39 months

            	 	 	
              0.221

            	 	 	 	
              0.246

            	 	 	 	
              0.269

            	 	 	 	
              0.290

            	 	 	 	
              0.309

            	 	 	 	
              0.325

            	 	 	 	
              0.340

            	 	 	 	
              0.354

            	 	 	 	
              0.364

            	 
	
              36 months

            	 	 	
              0.213

            	 	 	 	
              0.239

            	 	 	 	
              0.263

            	 	 	 	
              0.285

            	 	 	 	
              0.305

            	 	 	 	
              0.323

            	 	 	 	
              0.339

            	 	 	 	
              0.353

            	 	 	 	
              0.364

            	 
	
              33 months

            	 	 	
              0.205

            	 	 	 	
              0.232

            	 	 	 	
              0.257

            	 	 	 	
              0.280

            	 	 	 	
              0.301

            	 	 	 	
              0.320

            	 	 	 	
              0.337

            	 	 	 	
              0.352

            	 	 	 	
              0.364

            	 
	
              30 months

            	 	 	
              0.196

            	 	 	 	
              0.224

            	 	 	 	
              0.250

            	 	 	 	
              0.274

            	 	 	 	
              0.297

            	 	 	 	
              0.316

            	 	 	 	
              0.335

            	 	 	 	
              0.351

            	 	 	 	
              0.364

            	 
	
              27 months

            	 	 	
              0.185

            	 	 	 	
              0.214

            	 	 	 	
              0.242

            	 	 	 	
              0.268

            	 	 	 	
              0.291

            	 	 	 	
              0.313

            	 	 	 	
              0.332

            	 	 	 	
              0.350

            	 	 	 	
              0.364

            	 
	
              24 months

            	 	 	
              0.173

            	 	 	 	
              0.204

            	 	 	 	
              0.233

            	 	 	 	
              0.260

            	 	 	 	
              0.285

            	 	 	 	
              0.308

            	 	 	 	
              0.329

            	 	 	 	
              0.348

            	 	 	 	
              0.364

            	 
	
              21 months

            	 	 	
              0.161

            	 	 	 	
              0.193

            	 	 	 	
              0.223

            	 	 	 	
              0.252

            	 	 	 	
              0.279

            	 	 	 	
              0.304

            	 	 	 	
              0.326

            	 	 	 	
              0.347

            	 	 	 	
              0.364

            	 
	
              18 months

            	 	 	
              0.146

            	 	 	 	
              0.179

            	 	 	 	
              0.211

            	 	 	 	
              0.242

            	 	 	 	
              0.271

            	 	 	 	
              0.298

            	 	 	 	
              0.322

            	 	 	 	
              0.345

            	 	 	 	
              0.363

            	 
	
              15 months

            	 	 	
              0.130

            	 	 	 	
              0.164

            	 	 	 	
              0.197

            	 	 	 	
              0.230

            	 	 	 	
              0.262

            	 	 	 	
              0.291

            	 	 	 	
              0.317

            	 	 	 	
              0.342

            	 	 	 	
              0.363

            	 
	
              12 months

            	 	 	
              0.111

            	 	 	 	
              0.146

            	 	 	 	
              0.181

            	 	 	 	
              0.216

            	 	 	 	
              0.250

            	 	 	 	
              0.282

            	 	 	 	
              0.312

            	 	 	 	
              0.339

            	 	 	 	
              0.363

            	 
	
              9 months

            	 	 	
              0.090

            	 	 	 	
              0.125

            	 	 	 	
              0.162

            	 	 	 	
              0.199

            	 	 	 	
              0.237

            	 	 	 	
              0.272

            	 	 	 	
              0.305

            	 	 	 	
              0.336

            	 	 	 	
              0.362

            	 
	
              6 months

            	 	 	
              0.065

            	 	 	 	
              0.099

            	 	 	 	
              0.137

            	 	 	 	
              0.178

            	 	 	 	
              0.219

            	 	 	 	
              0.259

            	 	 	 	
              0.296

            	 	 	 	
              0.331

            	 	 	 	
              0.362

            	 
	
              3 months

            	 	 	
              0.034

            	 	 	 	
              0.065

            	 	 	 	
              0.104

            	 	 	 	
              0.150

            	 	 	 	
              0.197

            	 	 	 	
              0.243

            	 	 	 	
              0.286

            	 	 	 	
              0.326

            	 	 	 	
              0.361

            	 
	
              0 months

            	 	 	
              —

            	 	 	 	
              —

            	 	 	 	
              0.042

            	 	 	 	
              0.115

            	 	 	 	
              0.179

            	 	 	 	
              0.233

            	 	 	 	
              0.281

            	 	 	 	
              0.323

            	 	 	 	
              0.361

            	 

      
        
          

      

      The exact Fair Market Value and Redemption Date (as defined below) may not be set forth in the table above, in which case, if the Fair Market Value is between two values in the
        table or the Redemption Date is between two redemption dates in the table, the number of Ordinary Shares to be issued for each Warrant redeemed will be determined by a straight-line interpolation between the number of shares set forth for the
        higher and lower Fair Market Values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.

       

      

      The stock prices set forth in the column headings of the table above shall be adjusted as of any date on which the number of shares issuable upon exercise of a Warrant is adjusted
        pursuant to Section 4. The adjusted stock prices in the column headings shall equal the stock prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a
        Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. The number of shares in the table above shall be adjusted in the same manner and at the same
        time as the number of shares issuable upon exercise of a Warrant.

       

        

      6.3 Date Fixed for, and Notice of, Redemption.  In the event that the Company elects to redeem all of the Warrants
          pursuant to Section 6.1, the Company shall fix a date for the redemption (the “Redemption Date”).  In the event that the Company elects to redeem all of the Warrants pursuant to
          Section 6.2, the Company shall fix a date for redemption (the “Alternative Redemption Date”). Notice of redemption shall be mailed by first
          class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date or the Alternative Redemption Date, as applicable (such 30-day period, the “Redemption
            Period”), to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books.  Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly
          given whether or not the Registered Holder received such notice.

       

        

      6.4 Exercise After Notice of Redemption.  The Warrants may be exercised for cash (or on a “cashless basis” in accordance
          with subsection 3.3.1(b) of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.3 hereof and prior to the Redemption Date.  In the event that the Company determines to
          require all holders of Warrants to exercise their Warrants on a “cashless basis” pursuant to subsection 3.3.1, the notice of redemption shall contain the information necessary to calculate the number of Ordinary Shares to be received upon
          exercise of the Warrants, including the “Fair Market Value” (as such term is defined in subsection 3.3.1(b) hereof) in such case.  On and after the Redemption Date or the Alternative Redemption Date, as applicable, the record holder of
          the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price or the Alternative Redemption Price, as applicable.

       

        

      6.5 Exclusion of Private Placement Warrants.  The Company agrees that the redemption rights provided in this Section
            6 shall not apply to the Private Placement Warrants if at the time of the redemption such Private Placement Warrants continue to be held by the Sponsor or its Permitted Transferees.  However, once such Private Placement Warrants are
          transferred (other than to Permitted Transferees under Section 2.6), the Company may redeem the Private Placement Warrants, provided that the criteria for redemption are met, including the opportunity of the holder of such Private
          Placement Warrants to exercise the Private Placement Warrants prior to redemption pursuant to Section 6.1.  Private Placement Warrants that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be
          Private Placement Warrants and shall become Public Warrants under this Agreement.  The restrictions set forth under this Section 6.5 shall not apply to redemptions pursuant to Section 6.2 hereof.

      
        
          

      

      7. Repurchase of Public Warrants.

       

        

      7.1 Sponsor’s Obligation to Repurchase.  Each holder of Public Warrants (other than the Sponsor and its affiliates) may
          require the Sponsor to repurchase or cause one of its affiliates to repurchase, at $1.00 per Public Warrant (exclusive of commissions), the outstanding Public Warrants in connection with (i) the completion of the Company’s Business Combination,
          (ii) a proposed amendment to the Company’s Charter that would affect the substance or timing of the Company’s obligation to redeem 100% of its public Ordinary Shares if the Company does not complete a Business Combination within eighteen (18)
          months from the closing of the Offering or (iii) a proposed amendment to the terms of the Company’s Public Warrants that would affect the substance or timing of the right of holders of the Company’s Public Warrants to receive $1.00 per Public
          Warrant in the circumstances described in this Section 7, in which case any such purchases under (ii) and (iii) hereof would occur in connection with the effectiveness of such amendment. In the event a Business Combination is announced,
          but the Business Combination is later abandoned, the Sponsor or its affiliate will not repurchase the Public Warrants, and the Public Warrants will be returned to the holders.  In the event that the Company is unable to close a Business
          Combination within the allotted time, the escrow agent under the escrow created by the Sponsor or an affiliate pursuant to Section 7.3 shall be authorized and instructed to transfer $1.00 per whole Public Warrant, to holders of Public
          Warrants other than the Sponsor and its affiliates, at the same time as the Company redeems its public Ordinary Shares, and all Public Warrants shall expire worthless.

       

        

      7.2 Cancellation of Public Warrants.  Any Public Warrants repurchased pursuant to Section 7.1 will be cancelled
          and cease to exist.

       

        

      7.3 Escrow Account.  On the date hereof, the Sponsor or an affiliate will deposit cash funds in an amount equal to
          $7,500,000 (or $8,625,000 if the Over-allotment Option is exercised in full) into an escrow account maintained by the Warrant Agent at J.P. Morgan Chase Bank, N.A., which funds may be used to pay $1.00 per Public Warrant (other than Public
          Warrants held by the Sponsor and its affiliates) in connection with the events described under Section 7.1.  For the avoidance of doubt, funds in the escrow account shall not be held in trust or comprise any portion of any pro-rata
          distribution from the Company’s trust account.  Following a repurchase or payment to holders of Public Warrants in accordance with this Section 7, any amounts remaining in the escrow account will be returned to the Sponsor or its
          affiliate.

       

        

      8. Other Provisions Relating to Rights of Holders of Warrants.

       

        

      8.1 No Rights as Shareholder.  A Warrant does not entitle the Registered Holder thereof to any of the rights of a
          shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of
          shareholders or the election of directors of the Company or any other matter.

      
        
          

      

      8.2 Lost, Stolen, Mutilated, or Destroyed Warrants.  If any Warrant is lost, stolen, mutilated, or destroyed, the
          Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor,
          and date as the Warrant so lost, stolen, mutilated, or destroyed.  Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at
          any time enforceable by anyone.

       

        

      8.3 Reservation of Ordinary Shares.  The Company shall at all times reserve and keep available a number of its
          authorized but unissued Ordinary Shares that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

       

        

      8.4 Registration of Ordinary Shares; Cashless Exercise at Company’s Option.

       

        

      8.4.1 Registration of Ordinary Shares.  The Company agrees that as soon as practicable, but in no event later than
          thirty (30) business days after the closing of its initial Business Combination, it shall use its best efforts to file with the Commission a registration statement registering, under the Securities Act, the issuance of the Ordinary Shares
          issuable upon exercise of the Warrants.  The Company shall use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the
          expiration of the Warrants in accordance with the provisions of this Agreement.  If any such registration statement has not been declared effective by the 60th day
          following the closing of the Business Combination, holders of the Warrants shall have the right, during the period beginning on the 61st business day after the closing of the Business Combination and ending upon such registration statement being
          declared effective by the Commission, and during any other period when the Company shall fail to have maintained an effective registration statement covering the Ordinary Shares issuable upon exercise of the Warrants, to exercise such Warrants on
          a “cashless basis,” by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product
          of the number of Ordinary Shares underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) over the Warrant Price by (y) the Fair Market Value.  Solely for purposes of this subsection 8.4.1, “Fair
          Market Value” shall mean the average reported closing price of the Class A Ordinary Shares for the ten (10) trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the Warrant Agent.  The
          date that notice of cashless exercise is received by the Warrant Agent shall be conclusively determined by the Warrant Agent.  In connection with the “cashless exercise” of a Public Warrant, the Company shall, upon request, provide the Warrant
          Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a cashless basis in accordance with this subsection 8.4.1 is not
          required to be registered under the Securities Act and (ii) the Ordinary Shares issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144
          under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear a restrictive legend.  Except as provided in this subsection 8.4, for the avoidance of any doubt, unless and until all of the
          Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this subsection 8.4.

      
        
          

      

      8.4.2 Cashless Exercise at Company’s Option.  If the Ordinary Shares are at the time of any exercise of a Warrant not
          listed on a national securities exchange such that they satisfy the definition of “covered securities” under Section 18(b)(1) of the Securities Act (or any successor rule), the Company may, at its option, require holders of Public Warrants who
          exercise Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) as described in subsection 8.4.1, and (i) in the event the Company so elects
          to require a holder of Public Warrants who exercises Public Warrants to exercise such Public Warrants on a “cashless basis,” the Company shall not be required to file or maintain in effect a registration statement for the registration, under the
          Securities Act, of the Ordinary Shares issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary or (ii) if the Company does not so elect at the time of exercise to require a holder of Public Warrants who
          exercises Public Warrants to exercise such Public Warrants on a “cashless basis,” the Company agrees to use its best efforts to register or qualify for sale the Ordinary Shares issuable upon exercise of the Public Warrants under the blue sky laws
          of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available.

       

        

      9. Concerning the Warrant Agent and Other Matters.

       

        

      9.1 Payment of Taxes.  The Company shall from time to time promptly pay all taxes and charges that may be imposed upon
          the Company or the Warrant Agent in respect of the issuance or delivery of Ordinary Shares upon the exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

       

        

      9.2 Resignation, Consolidation, or Merger of Warrant Agent.

       

        

      9.2.1 Appointment of Successor Warrant Agent.  The Warrant Agent, or any successor to it hereafter appointed, may
          resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company.  If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or
          otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent.  If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such
          resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State
          of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost.  Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under
          the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or
          examination by federal or state authority.  After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if
          originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument
          transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all
          instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

      
        
          

      

      9.2.2 Notice of Successor Warrant Agent.  In the event a successor Warrant Agent shall be appointed, the Company shall
          give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Ordinary Shares not later than the effective date of any such appointment.

       

        

      9.2.3 Merger or Consolidation of Warrant Agent.  Any corporation into which the Warrant Agent may be merged or with
          which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

       

        

      9.3 Fees and Expenses of Warrant Agent.

       

        

      9.3.1 Remuneration.  The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such
          Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

       

        

      9.3.2 Further Assurances.  The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed,
          executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.

       

        

      9.4 Liability of Warrant Agent.

       

        

      9.4.1 Reliance on Company Statement.  Whenever in the performance of its duties under this Agreement, the Warrant Agent
          shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically
          prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, Secretary or Chairman of the Board of the Company and delivered to the Warrant Agent.  The Warrant
          Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

       

        

      9.4.2 Indemnity.  The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or
          bad faith.  The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this
          Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

       

        

      9.4.3 Exclusions.  The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or
          with respect to the validity or execution of any Warrant (except its countersignature thereof).  The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. 
          The Warrant Agent shall not be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts
          that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any Ordinary Shares to be issued pursuant to this Agreement or any Warrant or as
          to whether any Ordinary Shares shall, when issued, be valid and fully paid and non-assessable.

      
        
          

      

      9.5 Acceptance of Agency.  The Warrant Agent hereby accepts the agency established by this Agreement and agrees to
          perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the
          Warrant Agent for the purchase of Ordinary Shares through the exercise of the Warrants.

       

        

      9.6 Waiver.  The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the
          Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.  The Warrant Agent hereby waives any and all Claims against the
          Trust Account and any and all rights to seek access to the Trust Account.

       

        

      10. Miscellaneous Provisions.

       

        

      10.1 Successors.  All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant
          Agent shall bind and inure to the benefit of their respective successors and assigns.

       

        

      10.2 Notices.  Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or
          by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage
          prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:

       

      

      
        	
                SC Health Corporation

              	 
	 	
                108 Robinson Road #10-00

              
	 	
                Singapore 068900

              
	 	
                Attention: Angelo John Coloma

              

      

       

      

       

      Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so
        delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with
        the Company), as follows:

      
        

        

        
          	 	
                  American Stock Transfer & Trust Company, LLC

                
	 	
                  6201 15th Avenue

                
	 	
                  Brooklyn, NY 11219

                
	 	
                  Attention: AST Shareholder Services

                

        

      

    

     
    
      
        

    

    
      10.3 Applicable Law.  The validity, interpretation, and performance of this Agreement and of the Warrants shall be
          governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.  The Company hereby agrees that any action,
          proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably
          submits to such jurisdiction, which jurisdiction shall be exclusive.  The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.

       

        

      10.4 Persons Having Rights under this Agreement.  Nothing in this Agreement shall be construed to confer upon, or give
          to, any person or corporation other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.  All
          covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.

       

        

      10.5 Examination of the Warrant Agreement.  A copy of this Agreement shall be available at all reasonable times at the
          office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant.  The Warrant Agent may require any such holder to submit such holder’s Warrant for inspection by the
          Warrant Agent.

       

        

      10.6 Counterparts.  This Agreement may be executed in any number of original or facsimile counterparts and each of such
          counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

       

        

      10.7 Effect of Headings.  The section headings herein are for convenience only and are not part of this Agreement and
          shall not affect the interpretation thereof.

       

        

      10.8 Amendments.  This Agreement may be amended by the parties hereto without the consent of any Registered Holder (i)
          for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties
          may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the Registered Holders, and (ii) to provide for the delivery of Alternative Issuance pursuant to Section 4.4.  All other modifications or
          amendments, including any modification or amendment to increase the Warrant Price or shorten the Exercise Period and any amendment to the terms of only the Private Placement Warrants, shall require the vote or written consent of the Registered
          Holders of 50% of the number of the then outstanding Public Warrants and Forward Purchase Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants or any provision of this Agreement with respect to the
          Private Placement Warrants, 50% of the number of the then outstanding Private Placement Warrants.  Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period pursuant to Sections 3.1
          and 3.2, respectively, without the consent of the Registered Holders.  Notwithstanding anything to the contrary herein, after the issuance of the Forward Purchase Warrants and prior to the effectiveness of a registration statement
          covering the resale of the Forward Purchase Warrants and the Class A Ordinary Shares underlying such Forward Purchase Warrants, any modification or amendment to the terms of the Forward Purchase Warrants shall require the vote or written consent
          of the Registered Holders of 50% of the number of the then outstanding Forward Purchase Warrants.  Upon effectiveness of the registration statement covering the resale of the Forward Purchase Warrants and the Class A Ordinary Shares underlying
          such Forward Purchase Warrants, the Public Warrants and Forward Purchase Warrants will vote together as a single class on all matters submitted to a vote of the holders of the Warrants.

      
        
          

      

      10.9 Severability.  This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or
          provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof.  Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall
          be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

       

        

      Exhibit A: Legend — Private Placement Warrants

       

      

      Exhibit B: Form of Warrant Certificate

      
        
          

      

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

       

      

      	 	
              SC HEALTH CORPORATION

            
	 	 	 
	 	
              By:

            	/s/ David Sin

            
	 	 	
              Name: David Sin

              

            
	 	 	
              Title: Director

              

            
	 	 	 
	 	
              AMERICAN STOCK TRANSFER & TRUST

              COMPANY, LLC, as Warrant Agent

            
	 	 	 
	 	
              By:

            	/s/ Michael A. Nespoli

            
	 	 	
              Name: Michael A. Nespoli

              

            
	 	 	
              Title: Executive Director

              

            
	 	 
	 	
              SC HEALTH HOLDINGS LIMITED

            
	 	 	 
	 	
              By:

            	/s/ David Sin

            
	 	 	
              Name: David Sin

              

            
	 	 	
              Title: Director 

              

            
	 	 	 
	 	 	 

      
        
          

      

      EXHIBIT A

       

      

      LEGEND

       

      

      THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR
        OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE.  IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED
        IN THE AGREEMENTS BY AND AMONG SC HEALTH CORPORATION (THE “COMPANY”), SC HEALTH HOLDINGS LIMITED AND ANY OTHER SIGNATORIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30)
        DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT) WHO
        AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

        

      

      SECURITIES EVIDENCED BY THIS CERTIFICATE AND ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO
        BE EXECUTED BY THE COMPANY.

      
        
          

      

      EXHIBIT B

       

      

      [Form of Warrant Certificate]

      

        [FACE]

       

      

      Number

       

      

      Warrants

       

      

      THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO

        THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE

        WARRANT AGREEMENT DESCRIBED BELOW

      

      

      SC Health Corporation

      

      

      Incorporated Under the Laws of the Cayman Islands

      CUSIP [•]

      Warrant Certificate

      

      

      This Warrant Certificate certifies that                   , or registered assigns, is the registered holder
          of warrants (the “Warrants”) to purchase Class A Ordinary Shares, $0.0001 par value (the “Ordinary Shares”), of SC Health Corporation, a Cayman Islands exempted company (the “Company”). Each whole Warrant entitles the holder, upon exercise during the Exercise Period set forth in the Warrant Agreement referred to below, to receive from the Company
          that number of fully paid and non-assessable Ordinary Shares (each, a “Warrant”) as set forth below, at the exercise
          price (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through
          “cashless exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to
          the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

      

      

      Each whole Warrant is initially exercisable for one fully paid and non-assessable Ordinary Share. No fractional shares will be issued upon exercise of any Warrant. If, upon the
        exercise of Warrants, a holder would be entitled to receive a fractional interest in an Ordinary Share, the Company will, upon exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to the Warrant holder. The
        number of the Ordinary Shares issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

      

      

      The initial Exercise Price per Ordinary Share for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon the occurrence of certain events set forth in the Warrant
        Agreement.

      
        
          

      

      Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such
        Exercise Period, such Warrants shall become void.

      

      

      Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same
        effect as though fully set forth at this place.

      

      

      This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

      

      

      This Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.

      

      

      	 	
              SC HEALTH CORPORATION

            
	 	 	 
	 	
              By:

            	

            
	 	 	
              Name: 

              

            
	 	 	
              Title: 

              

            
	 	 	 
	 	
              AMERICAN STOCK TRANSFER & TRUST

            
	 	
              COMPANY, LLC as Warrant Agent

            
	 	 	 
	 	
              By:

            	

            
	 	 	
              Name: 

              

            
	 

            	 	
              Title: 

              

            

      
        
          

      

       [Form of Warrant Certificate]

      

      

      [Reverse]

      

      

      The Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive Ordinary Shares and are issued or to
        be issued pursuant to a Warrant Agreement dated as of (the “Warrant Agreement”), duly executed and delivered by the Company
        to American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as warrant agent (the “Warrant Agent”),

        which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent,
        the Company and the holders (the words “holders” or “holder” meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined
        terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

      

      

      Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them
        by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise” as
        provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants
        evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.

      

      

      Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering
        the Ordinary Shares to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating to the Ordinary Shares is current, except through “cashless exercise” as provided for in the Warrant Agreement.

      

      

      The Warrant Agreement provides that upon the occurrence of certain events the number of Ordinary Shares issuable upon the exercise of the Warrants set forth on the face hereof may,
        subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest whole number of
        Ordinary Shares to be issued to the holder of the Warrant.

      

      

      Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative or
        attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor
        evidencing in the aggregate a like number of Warrants.

      
        
          

      

      Upon due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor
        and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other
        governmental charge imposed in connection therewith.

      

      

      The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of ownership
        or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.
        Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a shareholder of the Company.

      
        
          

      

      Election to Purchase

      

      

      (To Be Executed Upon Exercise of Warrant)

      

      

      The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive  Ordinary Shares and herewith tenders payment for such Ordinary
        Shares to the order of SC Health Corporation (the “Company”) in the amount of $           in accordance with the terms
        hereof. The undersigned requests that a certificate for such Ordinary Shares be registered in the name of whose address is and that such Ordinary Shares be delivered to whose address is                       . If said number of shares is less than
        all of the Ordinary Shares purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary Shares be registered in the name of            , whose address is and that such Warrant
        Certificate be delivered to                       , whose address is                       .

      

      

      In the event that the Warrant has been called for redemption by the Company pursuant to Section 6 of the Warrant Agreement and the Company has required cashless exercise
        pursuant to Section 6.5 of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(b) and Section 6.5 of the Warrant Agreement.

      

      

      In the event that the Warrant is a Private Placement Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the
        number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

      

      

      In the event that the Warrant is to be exercised on a “cashless” basis pursuant to Section 9.4 of the Warrant Agreement, the number of Ordinary Shares that this Warrant is
        exercisable for shall be determined in accordance with Section 9.4 of the Warrant Agreement.

      

      

      In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of Ordinary Shares that this Warrant is
        exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to
        exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive Ordinary Shares. If said number of shares is less than all of the Ordinary Shares purchasable hereunder
        (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary Shares be registered in the name of            , whose address is and that such Warrant
        Certificate be delivered to            , whose address is                       .

      

      

      [Signature Page Follows]

      
        
          

      

      

      

      	
              Date:                 , 20

            	 
	 	
              (Signature)

            
	 	 
	 	 
	 	 
	 	
              (Address)

            
	 	
              

              

            
	 	
              (Tax Identification Number)

            
	
              Signature Guaranteed:

            	 
	 	 
	 	 

      THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE
        MEDALLION PROGRAM, PURSUANT TO SEC RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE).Exhibit 10.1

    

     

      

    
      Execution Version

       

        

      July 11, 2019

       

     

    

    
      SC Health Corporation

      108 Robinson Road #10-00

      Singapore 068900

      

      

      Re:          Initial Public Offering

      

      

      Ladies and Gentlemen:

      

      

      This letter (this “Letter Agreement”) is being delivered to you in accordance with the
        Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and among SC Health Corporation, a Cayman Islands exempted company (the “Company”), and Credit Suisse Securities (USA) LLC, as representative (the “Representative”), of the several underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”) of 17,250,000 of the Company’s units (including up to 2,250,000
        units that may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one of the Company’s Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), and one-half of one redeemable warrant (each whole warrant, a “Warrant”).  Each Warrant entitles the holder
        thereof to purchase one Ordinary Share at a price of $11.50 per share, subject to adjustment.  The Units will be sold in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the “Prospectus”) filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) and the Company has applied to have the Units listed on
        the New York Stock Exchange (the “NYSE”).  Certain capitalized terms used herein are defined in paragraph 15 hereof.

      

      

      In order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good
        and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”), and each of the
        undersigned individuals, each of whom is a member of the Company’s board of directors (the “Board”) and/or member of the Company’s management team (each, an “Insider” and collectively, the “Insiders”), hereby agrees with the Company as follows:

      

      

      1.    Each of the Sponsor and each Insider agrees that if the Company
          seeks shareholder approval of a proposed Business Combination, then in connection with such proposed Business Combination, it, he or she shall (i) vote any Ordinary Shares owned by it, him or her in favor of the proposed Business Combination and
          (ii) not redeem any Ordinary Shares owned by it, him or her in connection with such shareholder approval.

      
        
          

      

      
      2.    Each of the Sponsor and each Insider hereby agrees that in the
          event that the Company fails to consummate a Business Combination within 18 months from the closing of the Public Offering, or such later period approved by the Company’s shareholders in accordance with the Company’s amended and restated
          memorandum and articles of association (the “Charter”), the Sponsor and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations except for the
          purpose of winding up, (ii) as promptly as reasonably possible but not more than 10 business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Ordinary Shares sold as part of the Units in the Public Offering (the “Offering Shares”), at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay
          dissolution expenses and net of taxes payable), divided by the number of then outstanding Offering Shares, which redemption will completely extinguish all Public Shareholders’ rights as shareholders (including the right to receive further
          liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Board, dissolve and liquidate, subject
          in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and other requirements of applicable law.  Each of the Sponsor and each Insider agrees not to propose any amendment to the Charter to modify the
          substance or timing of the Company’s obligation to redeem 100% of the Offering Shares if the Company does not complete a Business Combination within 18 months from the closing of the Public Offering, (i) unless the Company provides its Public
          Shareholders with the opportunity to redeem their Offering Shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (net of taxes
          payable), divided by the number of then outstanding Offering Shares and (ii) each holder of the Warrants is provided the right to require the Sponsor or its affiliate to repurchase, at $1.00 per Warrant (exclusive of commissions), the outstanding
          Warrants, as described in the Warrant Agreement, dated July 11, 2019, among the Company, the Sponsor and American Stock Transfer & Trust Company, LLC.

       

      

      3.    The Sponsor and each Insider acknowledges that it, he or she
          has no right, title, interest or claim of any kind in or to any monies held in the Trust Account or any other asset of the Company as a result of any liquidation of the Company with respect to the Founder Shares held by it, him or her.  The
          Sponsor and each Insider hereby further waives (i) with respect to any Founder Shares and any Offering Shares held by it, him or her, any redemption rights it, he or she may have in connection with the consummation of a Business Combination, 
          (ii) with respect to any Founder Shares and any Offering Shares held by it, him or her, any redemption rights available in the context of a shareholder vote to approve such Business Combination or a shareholder vote to approve an amendment to the
          Charter to modify the substance or timing of the Company’s obligation to redeem 100% of the Offering Shares if the Company has not consummated a Business Combination within the later of (x) 18 months from the closing of the Public Offering and
          (y) such later date as may be approved by the Company’s shareholders in accordance with the Charter and (iii) with respect to any Founder Shares held by it, him or her, any rights to liquidating distributions from the Trust Account if the Company
          fails to consummate a Business Combination within the time period mentioned in (ii) above (although the Sponsor, the Insiders and their respective affiliates shall be entitled to redemption and liquidation rights with respect to any Offering
          Shares it or they hold if the Company fails to consummate a Business Combination within 18 months from the date of the closing of the Public Offering).

      
        -2-

        
          

      

      4.    Notwithstanding the provisions set forth in paragraphs 8(a)-(d)
          below, during the period commencing on the effective date of the Underwriting Agreement and ending 180 days after such date, the Sponsor and each Insider shall not, without the prior written consent of the Representatives, (i) sell, offer to
          sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call
          equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the Commission promulgated
          thereunder, with respect to any Units, Ordinary Shares, Warrants or any securities convertible into, or exercisable, or exchangeable for, Ordinary Shares owned by it, him or her (ii) enter into any swap or other arrangement that transfers to
          another, in whole or in part, any of the economic consequences of ownership of any Units, Ordinary Shares, Warrants or any securities convertible into, or exercisable, or exchangeable for, Ordinary Shares owned by it, him or her, whether any such
          transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii) publicly announce any intention to effect any transaction, including the filing of (or participation in the filing of) a registration statement, specified
          in clause (i) or (ii).  Each of the Insiders and the Sponsor acknowledges and agrees that, prior to the effective date of any release or waiver, of the restrictions set forth in this paragraph 4 or paragraph 8 below, the Company shall announce
          the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver.  Any release or waiver granted shall only be effective two business days after the
          publication date of such press release.  The provisions of this paragraph will not apply if (i) the release or waiver is effected solely to permit a transfer of securities that is not for consideration and (ii) the transferee has agreed in
          writing to be bound by the same terms described in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

       

      

      5.     In the event of the liquidation of the Trust Account upon the failure of the Company to consummate its initial Business Combination within the time period set forth in the Charter, the Sponsor (which for purposes of clarification shall
          not extend to any other shareholders, members or managers of the Sponsor) agrees to indemnify and hold harmless the Company against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all
          legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened, or any claim whatsoever) to which the Company may become subject as a result of any claim by (i) any third
          party for services rendered or products sold to the Company or (ii) any prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement (a “Target”); provided, however, that such indemnification of the Company by the Sponsor shall (x) apply only to the extent necessary to ensure that such claims by a third party
          or a Target do not reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Offering Share or (ii) the actual amount per Offering Share held in the Trust Account as of the date of the liquidation of the Trust Account,
          if less than $10.00 per Offering Share is then held in the Trust Account due to reductions in the value of the trust assets, in each case less taxes payable, (y) shall not apply to any claims by a third party or a Target which executed a waiver
          of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) and (z) shall not apply to any claims under the Company’s indemnity of the Underwriters against certain liabilities, including liabilities
          under the Securities Act of 1933, as amended.  The Sponsor shall have the right to defend against any such claim with counsel of its choice reasonably satisfactory to the Company if, within 15 days following written receipt of notice of the claim
          to the Sponsor, the Sponsor notifies the Company in writing that it shall undertake such defense.  For the avoidance of doubt, none of the Company’s officers or directors will indemnify the Company for claims by third parties, including, without
          limitation, claims by vendors and prospective target businesses.

      
        -3-

        
          

      

      6.    To the extent that the Underwriters do not exercise their
          over-allotment option to purchase up to an additional 2,250,000 Units within 45 days from the date of the Prospectus (and as further described in the Prospectus), the Sponsor agrees that it shall forfeit, at no cost, a number of Founder Shares in
          the aggregate equal to 562,500 multiplied by a fraction, (i) the numerator of which is 2,250,000 minus the number of Units purchased by the Underwriters upon the exercise of their over-allotment option, and (ii) the denominator of which is
          2,250,000.  All references in this Letter Agreement to Shares of the Company being forfeited shall take effect as surrenders for no consideration of such Shares as a matter of Cayman Islands law.  The forfeiture will be adjusted to the extent
          that the over-allotment option is not exercised in full by the Underwriters so that, on an as-converted basis, the Sponsor will own an aggregate of 20.0% of (i) the total number of Offering Shares (including any Offering Shares issued in
          connection with the Underwriters’ exercise of the over-allotment option), (ii) the number of Founder Shares held by the Sponsor and its permitted transferees following such forfeiture and (iii) the number of Forward Purchase Shares required to be
          purchased by the Forward Purchase Investor pursuant to the Forward Purchase Agreement.  Each of the Sponsor and each Insider further agrees that to the extent that the size of the Public Offering is increased or decreased, the Company will effect
          a capitalization or share surrender or redemption or other appropriate mechanism, as applicable, immediately prior to the consummation of the Public Offering in such amount as to maintain the ownership, on an as-converted basis, of the Sponsor at
          20.0% of (i) the total number of Offering Shares (including any Offering Shares issued in connection with the Underwriters’ exercise of the over-allotment option), (ii) the number of Founder Shares held by the Sponsor and its permitted
          transferees following such capitalization and (iii) the number of Forward Purchase Shares required to be purchased by the Forward Purchase Investor pursuant to the Forward Purchase Agreement.  In connection with such increase or decrease in the
          size of the Public Offering, then (i) the references to 2,250,000 in the numerator and denominator of the formula in the first sentence of this paragraph shall be changed to a number equal to 15.0% of the number of shares included in the Units
          issued in the Public Offering and (ii) the reference to 562,500 in the formula set forth in the immediately preceding sentence shall be adjusted to such number of Founder Shares that the Sponsor would have to return to the Company in order to
          hold (with the Forward Purchase Investor) an aggregate of 20.0% of (A) the total number of Offering Shares (including any Offering Shares issued in connection with the Underwriters’ exercise of the over-allotment option), (B) the number of
          Founder Shares held by the Sponsor following such capitalization and (C) the number of Forward Purchase Shares required to be purchased by the Forward Purchase Investor pursuant to the Forward Purchase Agreement.

       

      

      7.    Each of the Sponsor and each Insider who is an officer of the
          Company hereby agrees not to participate in the formation of, or become an officer or director of, any other blank check company until the Company has entered into a definitive agreement regarding an initial Business Combination or the Company
          has failed to complete an initial Business Combination within the time period set forth in the Charter.

      
        -4-

        
          

      

      8.    (a)      Each of the Sponsor and each Insider who is an officer of the Company agrees that it, he or she shall not Transfer any Founder Shares or any Ordinary Shares issued upon conversion thereof (the “Founder Shares Lock-up”) until the earlier of (A) one year after the completion of an initial Business Combination and (B) the date following the completion of the Company’s initial Business Combination on which the
          Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their Ordinary Shares for cash, securities or other property (the “Founder Shares Lock-up Period”).  Notwithstanding the foregoing, if (x) subsequent to the Company’s initial Business Combination, the closing price of the Ordinary Shares equals or exceeds
          $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s initial Business
          Combination or (y) if the Company consummates a liquidation, merger, share exchange or other similar transaction after the initial Business Combination which results in the Company’s shareholders having the right to exchange their shares for
          cash, securities or other property, the Founder Shares shall be released from the Founder Shares Lock-up.

      

      

         (b)    Each of the Sponsor and each Insider agrees that it, he or
          she shall not Transfer or assign any Private Placement Warrants (or Shares issued or issuable upon the exercise of the Private Placement Warrants), until 30 days after the completion of a Business Combination (the “Private Placement Warrants Lock-up Period”, together with the Founder Shares Lock-up Period, the “Lock-up Periods”).

      

      

          (c)    Notwithstanding the provisions set forth in paragraphs 8(a) and (b), Transfers of the Founder Shares, Private Placement Warrants and Ordinary Shares issued or issuable upon the exercise or conversion of the Private Placement Warrants or
          the Founder Shares and that are held by the Sponsor, any Insider or any of their permitted transferees (that have complied with this paragraph 8(c)), are permitted (i) to the Company’s officers or directors, any affiliate or family member of any
          of the Company’s officers or directors, any affiliate of the Sponsor or to any member of the Sponsor or any of their affiliates or shareholders, (ii) in the case of an individual, as a gift to such person’s immediate family or to a trust, the
          beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization; (iii) in the case of an individual, by virtue of laws of descent and distribution upon death of such person; (iv) in
          the case of an individual, pursuant to a qualified domestic relations order; (v) by private sales or transfers made in connection with the Forward Purchase Agreement or similar arrangement or in connection with the consummation of a Business
          Combination at prices no greater than the price at which the shares or warrants were originally purchased; (vi) by virtue of the laws of the Cayman Islands upon dissolution of the Sponsor, (vii) in the event of the Company’s liquidation prior to
          its consummation of its initial Business Combination; or (viii) in the event that, subsequent to its consummation of an initial Business Combination, the Company completes a liquidation, merger, share exchange or other similar transaction which
          results in all of its shareholders having the right to exchange their Ordinary Shares for cash, securities or other property; provided, however, that in the case of clauses (i) through (vi) these permitted transferees must enter into a written
          agreement with the Company agreeing to be bound by these transfer restrictions.

      
        -5-

        
          

      

      9.    Each of the Sponsor and each Insider represents and warrants
          that it, he or she has never been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked.  Each Insider’s biographical
          information furnished to the Company (including any such information included in the Prospectus) is true and accurate in all respects and does not omit any material information with respect to the Insider’s background.  The information in each
          Insider’s questionnaire furnished to the Company is true and accurate in all respects.  Each Insider represents and warrants that: it, he or she is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or
          order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; it, he or she has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any
          financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities and it, he or she is not currently a defendant in any such criminal proceeding.

      

      

      10.  Except as disclosed in the Prospectus, neither the Sponsor nor
          any Insider nor any affiliate of the Sponsor or any Insider, nor any director or officer of the Company, shall receive from the Company any finder’s fee, reimbursement, consulting fee, monies in respect of any repayment of a loan or other
          compensation prior to, or in connection with any services rendered in order to effectuate the consummation of the Company’s initial Business Combination (regardless of the type of transaction that it is), other than the following, none of which
          will be made from the proceeds of the Public Offering and the sale of the Private Placement Warrants held in the Trust Account prior to the completion of the initial Business Combination: repayment of a loan and advances of up to an aggregate of
          $300,000 made to the Company by the Sponsor; payment to an affiliate of the Sponsor for office space, utilities and secretarial and administrative support for a total of $10,000 per month; reimbursement for any reasonable out-of-pocket expenses
          related to identifying, investigating and consummating an initial Business Combination, and repayment of loans, if any, and on such terms as to be determined by the Company from time to time, made by the Sponsor or any of the Company’s officers
          or directors to finance transaction costs in connection with an intended initial Business Combination, provided, that, if the Company does not consummate an initial Business Combination, a portion of the working capital held outside the Trust
          Account may be used by the Company to repay such loaned amounts so long as no proceeds from the Trust Account are used for such repayment.  Up to $2,000,000 of such loans may be convertible into warrants at a price of $1.00 per warrant at the
          option of the lender.  Such warrants would be identical to the Private Placement Warrants, including as to exercise price, exercisability and exercise period.

      

      

      11.   Each of the Sponsor and each Insider has full right and power,
          without violating any agreement to which it is bound (including, without limitation, any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as applicable, to serve as a
          director on the Board and hereby consents to being named in the Prospectus as a director of the Company.

      

      

      12.  During the term of this Agreement, the Company shall, on a
          quarterly basis, reimburse each Independent Director for all reasonable out-of-pocket expenses incurred by each Independent Director in connection with fulfilling his service on the Board; provided, however, that each Independent Director
          complies with the applicable policies, practices and procedures of the Company and submits proper expense reports, receipts or similar documentation of such expenses as the Company may require.

      
        -6-

        
          

      

      13.  As used herein, (i) “Forward Purchase Investor” shall mean SC Health Group Limited, with whom the Company has entered into the Forward Purchase Agreement; (ii) “Business Combination” shall
          mean a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, involving the Company and one or more businesses; (iii) “Forward Purchase
            Agreement” shall mean the agreement providing for the sale of 5,000,000 Ordinary Shares and 1,250,000 Warrants to the Forward Purchase Investor in a private placement that will close concurrently with the closing of the initial Business
          Combination; (iv) “Forward Purchase Shares” shall mean the Ordinary Shares to be issued to the Forward Purchase Investor pursuant to the Forward Purchase Agreement; (v) “Founder Shares” shall mean the 5,562,500 Class B ordinary shares, par value $0.00008 per share, held by the Sponsor or its permitted transferees (or 5,000,000 shares if the over-allotment
          option is not exercised by the Underwriters in full); (vi) “Initial Shareholders” shall mean the Sponsor and any Insider that holds Founder Shares; (vii) “Private Placement Warrants” shall mean the Warrants to purchase up to 5,000,000 Ordinary Shares of the Company (or 5,540,000 Ordinary Shares if the over-allotment option is exercised in full) that the Sponsor has
          agreed to purchase for an aggregate purchase price of $5,000,000 in the aggregate (or $5,540,000 if the over-allotment option is exercised in full), or $1.00 per Warrant, in a private placement that shall occur simultaneously with the
          consummation of the Public Offering; (viii) “Public Shareholders” shall mean the holders of securities issued in the Public Offering; (ix) “Shares” shall mean, collectively, the Ordinary Shares and the Founder Shares; (x) “Trust Account” shall mean the trust fund into which a portion of the net proceeds of
          the Public Offering and the sale of the Private Placement Warrants shall be deposited; and (xi) “Transfer” shall mean the (a) sale of, offer to sell, contract or agreement to sell,
          hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call
          equivalent position within the meaning of Section 16 of the Exchange Act, and the rules and regulations of the Commission promulgated thereunder with respect to, any security, (b) entry into any swap or other arrangement that transfers to
          another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public announcement of any intention to effect
          any transaction specified in clause (a) or (b).

      

      

      14.  This Letter Agreement constitutes the entire agreement and
          understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the
          subject matter hereof or the transactions contemplated hereby.  This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument
          executed by all parties hereto.

      

      

      15.  No party hereto may assign either this Letter Agreement or any
          of its rights, interests, or obligations hereunder without the prior written consent of the other parties.  Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any
          interest or title to the purported assignee.  This Letter Agreement shall be binding on the Sponsor and each Insider and their respective successors, heirs and assigns and permitted transferees.

      

      

      16.  Nothing in this Letter Agreement shall be construed to confer
          upon, or give to, any person or corporation other than the parties hereto any right, remedy or claim under or by reason of this Letter Agreement or of any covenant, condition, stipulation, promise or agreement hereof.  All covenants, conditions,
          stipulations, promises and agreements contained in this Letter Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors, heirs, personal representatives and assigns and permitted transferees.

      

      

      17.  This Letter Agreement may be executed in any number of original
          or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

      
        -7-

        
          

      

      18.  This Letter Agreement shall be deemed severable, and the
          invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Letter Agreement or any other term or provision hereof.  Furthermore, in lieu of any such invalid or unenforceable term or
          provision, the parties hereto intend that there shall be added as part of this Letter Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

      

      

      19.  Each of the Sponsor and each Insider hereby agrees and
          acknowledges that: (i) the Underwriters and the Company may be irreparably injured in the event of a breach by such Sponsor or Insider of its, his or her obligations under paragraphs 1, 2, 4, 5, 6, 8(a), 8(b) and 10 of this Letter Agreement, (ii)
          monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the event of such breach.

      

      

      20.  This Letter Agreement shall be governed by and construed and
          enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.  The parties hereto (i) all agree that any
          action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and venue,
          which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.

      

      

      21.  Any notice, consent or request to be given in connection with
          any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile transmission.

      

      

      22.  This Letter Agreement shall terminate on the earlier of (i) the
          expiration of the Lock-up Periods or (ii) the liquidation of the Company; provided, however, that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated and closed by May 31, 2020;
          provided further that paragraph 5 of this Letter Agreement shall survive such liquidation.

      

      

      [Signature Page Follows]

      
        -8-

        
          

      

      
      	 	
              Sincerely,

            	 
	 	 	 	 
	 	
              SC HEALTH HOLDINGS LIMITED

            
	 	 	 	 
	 	
              By:

            	/s/ David Sin 	 
	 	
              Name:

            	David Sin 

            
	 	
              Title:

            	Director 

            
	 	 	 	 
	 	
              By:

            	/s/ David Sin 	 
	 	
              Name: David Sin

            
	 	 	 	 
	 	
              By:

            	/s/ Angelo John Coloma 	 
	 	
              Name: Angelo John Coloma

            
	 	 	 	 
	 	
              By:

            	/s/ Hwei Lynn Lau 

            	 
	 	
              Name: Hwei Lynn Lau

            
	 	 	 	 
	 	By:	/s/ Lim Cheok Peng 	 
	 	Name:	 Lim Cheok Peng

            	 
	 	 	 	 
	 	
              By:

            	/s/ Frank Lavin 	 
	 	
              Name: Frank Lavin

            
	 	 	 	 
	 	
              By:

            	/s/ Suresh Marimuthu 	 
	 	
              Name: Suresh Marimuthu

            

      

      

      Acknowledged and Agreed:

      

      

      	
              SC HEALTH CORPORATION

            
	 	 	 
	
              By:

            	/s/ David Sin 	 
	
              Name:

            	David Sin 

            	 
	
              Title:

            	Director 

            	 

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      [Signature Page to Letter Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]